# The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.

> **NCT06930118** · PHASE2 · RECRUITING · sponsor: **Shanghai Changzheng Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Colorectal Cancer in the Third-line Treatment and Beyond
- pMMR/MSS Advanced Colorectal Cancer

## Interventions

- **DRUG:** chidamide, regorafenib, and iparomlimab/tuvonralimab

## Key facts

- **NCT ID:** NCT06930118
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-10
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06930118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06930118, "The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06930118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*